Diligence memo · auto-generated · as of July 2, 2026
New Frontier Bio, Inc.
New Frontier Bio, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
New Frontier Bio, Inc. operates in Biotech / Pharma, based in BEVERLY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
New Frontier Bio, Inc. has raised $9.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.9M on 2022-09-13.
Most recent recorded round closed around 2024-05-13.
Valuation (modeled)modeled
Provath models New Frontier Bio, Inc. at approximately $1.7M (range $345K–$3.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.04× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round was 28.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 61% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 14% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.